Table of Contents

1. Executive Summary 4

2 Objectives and Methodology 5

3 Overview of M&A Activity 2015-2017 6

Target Characteristics 7

Acquirer Characteristics 11

4 Segment Close-Ups of M&A Activity, 2015-2017 15

Dose Manufacturing 15

API - Biologic 18

API - Small Molecule 19

Analytical Services 21

Formulation and Clinical Supplies Manufacturing 24

Packaging 26

5 Valuations 27

6 Facility Acquisitions 29

7 What It Means 36

8 The Outlook for M&A in the Manufacturing Services Industry 39

9 Notes on Methodology 41

10 Appendix 42

Service Acquisitions 2015-2017 42

Bibliography 49

Primary Research - Key Opinion Leaders Cited in this Report 49

About the Authors 50

PharmSource - M&A in the Contract Manufacturing Industry: Implications and Outlook - 2018 Edition

Summary

This report is the 2nd edition of our analysis of Mergers and Acquisitions in the contract manufacturing industry. PharmSource is the most definitive, trustworthy source of strategic insight on this topic in the bio/pharmaceutical realm.

Scope

- Helps bio/pharmaceutical manufacturing, development, and supply chain executives understand the implications of M&A activity on their supply base and sourcing options.
- Helps executives at CMOs and associated contract services companies and investors to recognize the significance of M&A activities for the competitive dynamics of the industry and how company strategies must change to address the altering market.
- To gain insights that might enable predictions of the nature and implications of M&A activity in the next three to five years.

Reasons to buy

This 52-page report gives important, expert insight you won’t find in any other source. 28 tables and figures throughout the report illustrate major points and trends. This report is required reading for -
- CMOs: market trends, strategic planning, competitive intelligence, performance benchmarking
- Bio/Pharma: supplier performance benchmarking, market trends, competitive intelligence
- Private equity and Stock analysts: target identification and analysis, portfolio company performance benchmarking.